Relative resistance of striatal neurons containing calbindin or parvalbumin to quinolinic acid-mediated excitotoxicity compared to other striatal neuron types

Experimental Neurology

Volumn 149, Issue 2, 1998, Pages 356-372

  Figueredo Cardenas, Griselle ^a   Harris, Cynthia L ^a   Anderson, Keith D ^a   Reiner, Anton ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Basal ganglia; Calcium binding proteins; Glutamate receptors; Neurodegeneration; Quinolinic acid

Indexed keywords

CALBINDIN; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPEPTIDE Y; PARVALBUMIN; QUINOLINIC ACID; SOMATOSTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASAL GANGLION; BRAIN ISCHEMIA; CELL LABELING; CELL SURVIVAL; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; INTERNEURON; MALE; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; STANDARDIZATION;

EID: 0032005414     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1997.6724     Document Type: Article

References (113)

1. Albin R. L., Greenamyre J. T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738.
2. Albin R. L., Reiner A., Anderson K. D., Penney J. B., Young A. B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: Implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27:1990;357-361.
3. Albin R. L., Reiner A., Anderson K. D., Dure L. S. IV, Handelin B., Balfour R., Whetsell W. O., Penney J. B., Young A. B. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 31:1992;425-430.
4. Albin R. L., Young A. B., Penney J. B., Handelin B., Balfour R., Anderson K. D., Markel D. S., Tourtellotte W. W., Reiner A. Abnormalities of striatal projection neurons andND. N. Engl. J. Med. 322:1990;1293-1298.
5. Anderson K. D., Reiner A. The extensive co-occurrence of substance P and dynorphin in striatal projection neurons: An evolutionarily conserved feature of basal ganglia organization. J. Comp. Neurol. 295:1990;339-369.
6. Anderson K. D., Reiner A. The distribution and relative abundance of neurons in the pigeon forebrain containing somatostatin, neuropeptide Y or both. J. Comp. Neurol. 299:1990;261-282.
7. Anderson K. D., Reiner A. Striatonigral projection neurons: A retrograde labeling study of the percentages that contain substance P or enkephalin. J. Comp. Neurol. 303:1991;658-673.
8. Anderson K. D., Reiner A. Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: Implications for the localization of D1 dopamine receptors on different types of striatal neurons. Brain Res. 568:1991;235-243.
9. Aronin N., Cooper P. E., Lorenz L. J., Bird E. D., Sagar S. M., Leeman S. E., Martin J. B. Somatostatin is increased in the basal ganglia in Huntington disease. Ann. Neurol. 13:1983;519-526.
10. Baimbridge K. G., Celio M. R., Rogers J. H. Calcium binding proteins in the nervous system. Trends Neurosci. 15:1992;303-308.
11. Bazzett T. J., Becker J. B., Katz K. W., Albin R. L. Chronic intrastriatal dialytic administration of quinolinc acid produces selective neural degeneration. Exp. Neurol. 120:1993;177-185.
12. Bazzett T. J., Becker J. B., Falik R. C., Albin R. L. Chronic intrastriatal quinolinic acid produces reversible changes in perikaryal calbindin and parvalbumin immunoreactivity. Neuroscience. 60:1994;837-841.
13. Beal M. F. Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol. 2:1992;657-662.
14. Beal M. F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses. Ann. Neurol. 31:1992;119-130.
15. Beal M. F., Bradley T. H., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases. Trends Neurosci. 16:1993;125-131.
16. Beal M. F., Brouillet E., Jenkins B. G., Ferrante R. J., Kowall N. W., Miller J. M., Storey E., Srivastava R., Rosen B. R., Hyman B. T. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitroproprionic acid. J. Neurosci. 13:1993;4181-4192.
17. Beal M. F., Ferrante R. J., Swartz K. J., Kowall N. W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11:1991;1649-1659.
18. Beal M. F., Kowall N. W., Ellison D. W., Mazurek M. F., Swartz K. J., Martin J. B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
19. Beal M. F., Kowall N. W., Swartz K. J., Ferrante R. J., Martin J. B. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse. 31:1989;38-47.
20. Beal M. F., Mazurek M. F., Ellison D. W., Swartz K. J., McGarvey U., Bird E. D., Martin J. B. Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann. Neurol. 23:1988;562-569.
21. Bennett B. D., Bolam J. P. Characterization of calretinin-immunoreactive structures in the striatum of the rat. Brain Res. 609:1993;137-148.
22. Boegman R. J., Smith Y., Parent A. Quinolinic acid does not spare striatal neuropeptide Y-immunoreactive neurons. Brain Res. 415:1987;178-182.
23. Buchan A., Li H., Chao S., Pulsinelli W. A. Blockade of the AMPA receptor prevents CA1 hippocampal injury following severe but transient forebrain ischemia in adult rats. Neurosci. Lett. 132:1991;255-258.
24. 2+. J. Cereb. Blood Flow Metab. 14:1994;903-910.
25. Buchan A., Li H., Pulsinelli W. A. TheND. J. Neurosci. 11:1991;1049-1056.
26. Burke R. E., Baimbridge K. G. Relative loss of the striatal striosome compartment, defined by calbindin-D29k immunostaining, following developmental hypoxic-ischemic injury. Neuroscience. 56:1993;305-315.
27. Celio M. R. Calbindin D-28K and parvalbumin in the rat nervous system. Neuroscience. 35:1990;375-475.
28. Celio M. R., Baier W., de Viragh P., Scharer E., Gerday C. Monoclonal antibodies directed against the calcium binding protein parvalbumin. Cell Calcium. 9:1988;81-86.
29. Chen Q., Harris C., Brown C. S., Howe A., Surmeier D. J., Reiner A. Glutamate-mediated excitotoxic death of cultured striatal neurons is mediated by non-NMDA glutamate receptors. Exp. Neurol. 136:1995;212-224.
30. Chen Q., Reiner A. Cellular distribution of the NMDA receptor NR2A/2B subunits in the rat striatum. Brain Res. 743:1997;346-352.
31. Chen Q., Veenman C. L., Reiner A. Cellular expression of ionotropic glutamate receptor subunits on specific striatal neuron types and its implication for striatal vulnerability in glutamate receptor-mediated excitotoxicity. Neuroscience. 73:1996;715-731.
32. Chesselet M. F., Gonzales C., Lin C. S., Polsky K., Jin B. K. Ischemic damage in the striatum of adults gerbils: Relative sparing of somatostatinergic and cholinergic interneurons contrasts with loss of efferent neurons. Exp. Neurol. 110:1990;209-218.
33. Choi D. W. Calcium-mediated neurotoxicity: Relationship to specific channel types and role in ischemic damage. Trends Neurosci. 11:1988;465-469.
34. Choi D. W. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1:1988;623-634.
35. Choi D. W., Rothman S. M. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13:1990;171-182.
36. Christie M. J., Beart P. M., Jarrot B., Maccarrone C. Distribution of neuropeptide Y immunoreactivity in the rat basal ganglia: Effects of excitotoxin lesions to caudate-putamen. Neurosci. Lett. 63:1986;305-309.
37. Cote P. Y., Sadikot A. F., Parent A. Complementary distribution of calbindin D28K and parvalbumin in the basal forebrain and midbrain of the squirrel monkey. Eur. J. Neurosci. 3:1991;1316-1329.
38. Cowan R. L., Wilson C. J., Emson P. C., Heizmann C. W. Parvalbumin-containing GABAergic interneurons in the rat neostriatum. J. Comp. Neurol. 302:1990;197-205.
39. Davies S. W., Roberts P. J. No evidence for preservation of somatostatin-containing neurons after intrastriatal injections of quinolinic acid. Nature. 327:1987;326-329.
40. Davies S. W., Roberts P. J. Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum. Neuroscience. 26:1988;387-393.
41. DiFiglia M., Christakos S., Aronin N. Ultrastructural localization of immunoreactive calbindin-D28k in the rat and monkey basal ganglia, including subcellular distribution with colloidal gold labeling. J. Comp. Neurol. 279:1989;653-665.
42. Ferrante R. J., Beal M. F., Kowall N. W., Richardson E. P., Martin J. B. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res. 411:1987;162-166.
43. Ferrante R. J., Kowall N. W., Beal M. F., Richardson E. P., Bird E. D., Martin J. B. Selective sparing of a class of striatal neurons in Huntington's disease. Science. 230:1985;561-563.
44. Ferrante R. J., Kowall N. W., Cippoloni P. B., Storey E., Beal M. F. Excitotoxin lesions in primates as a model for Huntington's disease: Histopathologic and neurochemical characterization. Exp. Neurol. 119:1993;46-71.
45. Ferrante R. J., Kowall N. W., Richardson E. P. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: A combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci. 11:1993;3877-3887.
46. Ferrer I., Kulisevsky J., Gonzalez G., Escartin A., Chivite A., Casas R. Parvalbumin-immunoreactive neurons in the cerebral cortex and striatum in Huntington's disease. Neurodegeneration. 3:1994;169-173.
47. Figueredo-Cardenas G., Anderson K. D., Chen Q., Veenman C. L., Reiner A. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 129:1994;37-56.
48. Figueredo-Cardenas G., Baxter K., Nowak T. S., Pulsinelli W. A., Reiner A. Global ischemia in rats yield striatal projection neuron and interneuron loss resembling Huntington's disease. Soc. Neurosci. Abstr. 19:1993;1652.
49. Figueredo-Cardenas G., Chen Q., Reiner A. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 146:1997;444-457.
50. Figueredo-Cardenas G., Medina L., Reiner A. Calretinin is localized to a unique population of striatal interneurons in rats. Brain Res. 709:1996;145-150.
51. Figueredo-Cardenas G., Morello M., Sancesario G., Bernardi G., Reiner A. Colocalization of somatostatin, neuropeptide Y, NADPH-diaphorase and neuronal nitric oxide synthase in striatal interneurons in rats. Brain Res. 735:1996;317-324.
52. Forloni G. L., Angeretti N., Rizzi M., Vezzani A. Chronic infusion of quinolinic acid in rat striatum: effects on discrete neuronal populations. J. Neurol. Sci. 108:1992;129-136.
53. Freund T. F., Buzzsaki G., Leon A., Baimbridge K. G., Somogyi P. Relationship of neuronal vulnerability and calcium binding protein immunoreactivity in ischemia. Exp. Brain Res. 83:1990;55-66.
54. Gerfen C. R., Baimbridge K. G., Miller J. J. The neostriatal mosaic: Compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc. Natl. Acad. Sci. USA. 82:1985;8780-8784.
55. Gerfen C. R., Young W. S. III. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res. 460:1988;161-167.
56. Gonzalez C., Lin R. C. S., Chesselet M. F. Relative sparing of GABAergic interneurons in the striatum of gerbils with ischemia-induced lesions. Neurosci. Lett. 135:1992;53-58.
57. Goodman J. H., Wasterlain C. G., Massarweh W. F., Dean E., Sollas A. L., Sloviter R. S. Calbindin-D28k immunoreactivity and selective vulnerability to ischemia in the dentate gyrus of the developing rat. Brain Res. 606:1993;309-314.
58. Goto S., Nagahiro S., Korematsu K., Ushio Y. Striatonigral involvement following transient focal cerebral ischemia in the rats: an immunohistochemical study on a reversible ischemia model. Acta Neuropathol. 85:1993;515-520.
59. 2+. Exp. Neurol. 121:1993;261-269.
60. Graybiel A. M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-254.
61. Harrington K. M., Kowall N. M. Parvalbumin immunoreactive neurons resist degeneration in Huntington's disease striatum. J. Neuropathol. Exp. Neurol. 50:1991;309.
62. Hedreen J. C., Folstein S. E. Early loss of neostriatal striosome neurons in Huntington's disease. J. Neuropath. Exp. Neurol. 54:1995;105-120.
63. 2+. Trends Neurosci. 15:1992;259-264.
64. de las Heras S., Hontanilla B., Mengual E., Gimenez-Amaya J. M. Immunohistochemical distribution of calbindin D-28k and parvalbumin in the head of the caudate nucleus and substantia nigra of the cat. J. Morphol. 221:1994;291-307.
65. Huang Q., Zhou D., Sapp E., Aizawa H., Ge P., Bird E. D., Vonsattel J. P., DiFiglia M. Quinolinic acid-induced increases in calbindin D28K immunoreactivity in rat striatal neuronsin vivoin vitro. Neuroscience. 65:1995;397-407.
66. Iacopino A., Christakos S., German D., Sonsalla P. K., Altar C. A. Calbindin-D28K-containing neurons in animal models of neurodegeneration: Possible protection from excitotoxicity. Mol. Brain Res. 13:1992;251-161.
67. Inagaki S., Suzuki K., Taniguchi N., Takagi H. Localization of Mn-superoxide dismutase (Mn-SOD) in cholinergic and somatostatin-containing neurons in the rat neostriatum. Brain Res. 549:1991;174-177.
68. Johansen F. F., Tonder N., Zimmer J., Baimbridge K. G., Diemer N. H. Short-term changes of parvalbumin and calbindin immunoreactivity in the rat hippocampus following cerebral ischemia. Neurosci. Lett. 120:1990;171-174.
69. Kanazawa I., Bird E. D., Gale J. S., Iversen L. L., Jessell T. M., Muramoto O., Spokes E. G., Sutoo D. Substance P: Decrease in substantia nigra and globus pallidus in Huntington's disease. Adv. Neurol. 23:1979;496-504.
70. Kawaguchi Y. Physiological, morphological, and histochemical characterization of three classes of interneurons in rat neostriatum. J. Neurosci. 13:1993;4908-4923.
71. Kawaguchi Y., Wilson C. J., Emson P. C. Projection subtypes of rat neostriatal matrix cells revealed by intracellular injection of biocytin. J. Neurosci. 10:1990;3421-3438.
72. Kirk R. E. Multiple comparison tests. Experimental Design: Procedures for the Behavioral Sciences. 1982;Brooks/Cole, Monterey. p. 106-110.
73. Kiyama H., Set-Ohshima A., Emson P. C. Calbindin D28k as a marker for the degeneration of the striatonigral pathway in Huntington's disease. Brain Res. 525:1990;209-214.
74. Kita H., Kosaka T., Heizmann C. W. Parvalbumin-immunoreactive neurons in the rat neostriatum: A light and electron microscopic study. Brain Res. 536:1990;1-15.
75. Kowall N. W., Ferrante R. J., Martin J. B. Pattern of cell loss in Huntington's disease. Trends Neurosci. 10:1987;24-29.
76. Landwehrmeyer G. B., Standaert D. G., Testa C. M., Penney J. B., Young A. B. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J. Neurosci. 15:1995;5297-5307.
77. 2+. Neurodegeneration. 4:1995;307-314.
78. Mattson M. P., Cheng B., Smith-Swintosky V. L. Mechanisms of neurotrophic factor protection in calcium-free radical-mediated excitoxic injury: Implications for treating neurodegenerative disorders. Exp. Neurol. 124:1993;89-95.
79. Medina L., Figueredo-Cardenas G., Reiner A. Differential abundance of superoxide dismutase in interneurons versus projection neurons in patch versus matrix neurons in monkey striatum. Brain Res. 708:1995;59-70.
80. 2+. Trends Pharmacol. Sci. 16:1995;356-359.
81. Mudrick L. A., Baimbridge K. G. Long term structural changes in the rat hippocampal formation following cerebral ischemia. Brain Res. 493:1989;179-184.
82. 2+. Brain Res. 613:1993;181-192.
83. 2+. Neurosci. Lett. 105:1989;263-268.
84. Novelli A., Reilly J. A., Lysko P. G., Henneberry R. C. Glutamate becomes neurotoxic via theND. Brain Res. 451:1988;205-212.
85. Orrenius S., Burkitt M. J., Kass G. E. N., Dypbukt J. M., Nicotera P. Calcium ions and oxidative cell injury. Ann. Neurol. 32:1992;S33-S42.
86. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
87. 2+. Eur. J. Pharmacol. 209:1991;169-173.
88. Qin Y., Soghomonian J. J., Chesselet M. F. Effects of quinolinic acid on messenger RNAs encoding somatostatin and glutamic acid decarboxylases in the striatum of adult rats. Exp. Neurol. 115:1992;200-211.
89. Reiner A. The distribution of proenkephalin-derived peptides in the central nervous system of turtle. J. Comp. Neurol. 259:1987;65-91.
90. Reiner A., Albin R. L., Anderson K. D., D'Amato C. J., Penney J. B., Young A. B. Differential loss of striatal projection neurons in Huntington's disease. Proc. Natl. Acad. Sci. USA. 85:1988;5733-5737.
91. Reiner A., Anderson K. D. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: Conclusions based on recent findings. Brain Res. Rev. 15:1990;251-265.
92. Richfield E. K., Herkenham M. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Ann. Neurol. 36:1994;577-584.
93. Richfield E. K., Maguire-Zeiss K. A., Cox C., Gilmore J., Voorn P. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann. Neurol. 37:1995;335-343.
94. Roberts R. C., DiFiglia M. Short- and long-term survival of large neurons in the excitotoxic lesioned rat caudate nucleus: A light and electron microscopic study. Synapse. 3:1989;363-371.
95. 2+. Eur. J. Pharmacol. 294:1995;469-473.
96. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A. B., von Sattel J. P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience. 64:1995;397-404.
97. Schoepfer R., Monter H., Sommer B., Wisden W., Sprengel R., Kuner T., Lomeli H., Herb A., Kohler R., Burnahev N., Gunther W., Ruppersberg P., Seeburg P. Molecular biology of glutamate receptors. Prog. Neurobiol. 42:1994;353-357.
98. Seto-Ohshima A., Emson P. C., Lawson E., Mountjoy C. Q., Carrasco L. H. Loss of matrix calcium binding protein containing neurons in Huntington's disease. Lancet. 1:1988;1252-1255.
99. Sheardown M. J., Suzdak P. D., Nordholm L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia, even when delayed 24 h. Eur. J. Pharmacol. 236:1993;347-353.
100. Siesjo B. Historical overview: Calcium, ischemia and death of brain cells. Ann. N. Y. Acad. Sci. 522:1988;638-661.
101. Sloviter R. S. Calcium binding protein (calbindin-D28k) and parvalbumin immunohistochemistry localization in the rat hippocampus with specific reference to the selective vulnerability of hippocampal neurons to seizure activity. J. Comp. Neurol. 280:1989;183-196.
102. Sloviter R. S., Sollas A. L., Barbaro N. M., Laxer K. D. Calcium binding protein (calbindin-D28k) and parvalbumin immunohistochemistry in the normal and epileptic hippocampus. J. Comp. Neurol. 308:1991;381-396.
103. Smith Y., Parent A. Neuropeptide Y-Immunoreactive neurons in the striatum of cat and monkey: Morphological characteristics, intrinsic organization and co-localization with somatostatin. Brain Res. 372:1986;241-252.
104. Tallaksen-Greene S. J., Albin R. L. Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience. 61:1994;509-519.
105. Takizawa S., Matsushima K., Fujita H., Nanri K., Ogawa S., Shinohara Y. A selective N-type calcium channel antagonist reduces extracellular glutamate release and infarct volume in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 15:1995;611-618.
106. Uemura Y., Kowall N. W., Beal M. F. Selective sparing of NADPH-diaphorase-somatostatin-neuropeptide Y neurons in ischemic gerbil striatum. Ann. Neurol. 27:1990;620-625.
107. Valentino K., Newcomb R., Gadbois T., Singh T., Bowlersox S., Bitner S., Justice A., Yamashiro D., Hoffman B. B., Ciaranello R., Miljanich G., Ramachandran J. A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia. Proc. Natl. Acad. Sci. USA. 90:1993;7894-7897.
108. Vincent S. R., Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience. 46:1992;755-784.
109. Vincent S. R., Johansson O. Striatal neurons containing both somatostatin and avian pancreatic polypeptide (APP)-like immunoreactivities and NADPH-diaphorase activity: A light and electron microscopic study. J. Comp. Neurol. 217:1983;252-263.
110. Waldvogel H. J., Faull R. L. M., Williams M. N., Dragunow M. Differential sensitivity of calbindin and parvalbumin immunoreactive cells in the striatum to excitotoxins. Brain Res. 546:1991;329-335.
111. Weiss J. H., Hartley D. M., Koh J., Choi D. W. The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science. 247:1990;1474-1477.
112. Weiss S., Hochman D., MacVicar B. A. Repeated NMDA receptor activation induces distinct intracellular calcium changes in subpopulations of striatal neurons in vitro. Brain Res. 627:1993;63-71.
113. Yakel J. L. Calcineurin regulation of synaptic function: From ion channels to transmitter release and gene transcription. Trends Pharmacol. Sci. 18:1997;124-134.